Navigation Links
Genetic Trait Could Predict Lung Cancer
Date:11/18/2008

But research is preliminary, scientists stress

TUESDAY, Nov. 18 (HealthDay News) -- Canadian scientists may have discovered a genetic trait that could provide an early indication of which former smokers will develop lung cancer.

The research, reported Tuesday at the American Association for Cancer Research conference in Washington, D.C., is still in the preliminary stages.

Still, "the benefit would hopefully be more targeted treatment," said study author Emily A. Vucic, a graduate student at British Columbia Cancer Research Centre in Vancouver.

While smoking rates continue to shrink, lung cancer remains the second most common cancer in the United States for both genders. According to the American Cancer Society, it trails only breast cancer (in women) and prostate cancer (in men).

The society estimates that 161,840 Americans will die this year from lung cancer. An estimated 85 percent to 90 percent of cases across the world are caused by smoking.

In the new study, Vucic and colleagues examined the DNA of eight former smokers who had undergone lung cancer surgery and eight former smokers who had not. The DNA was collected from tissue in their airways.

The researchers looked for signs of damage to the DNA in the cells that make up the tissue. If damage exists, genes in the cell may not be able to prevent the cells from multiplying and turning into cancer cells, Vucic said.

The DNA is "definitely affected by cigarette smoke," she said.

The study found that there were more signs of damage in the former smokers who developed lung cancer. It's possible that a simple mouth swab could provide DNA for testing and give doctors an idea of the lung-cancer prospects for patients, Vucic said.

The scientists now plan to enroll 100 people in a follow-up trial, Vucic said.

In another study to be released at the meeting, researchers reported that cruciferous vege
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetic Trait Could Predict Lung Cancer
Genetic Trait Could Predict Lung Cancer
(Date:11/21/2009)...isions of Legislation, Continues Push for Progress...ov. 21 With the U.S. ...rdable Health Care for America Act (H.R. 3962), an...forward, Congress has taken decisive steps to fix ...RP hosted an educational forum to discuss the prov...
(Date:11/21/2009)...l apparel company launches men,s lab coats at Medi...Clemente, Calif. (PRWEB) November 21, 2009 -- Mede...today announced the launch of its men,s lab coats,...ternational trade fair for the medical industry he...s men,s collection with three varying lab coat sty...
(Date:11/21/2009)...Group merges their practice with that of E. Steven... (PRWEB) November 21, 2009 -- The New Hav...ibson, Dr. Dean Cloutier, Dr. John Plachtyna and D...practice with that of esteemed colleague Dr. E. St...ed to retire from dentistry in order to concentrat...
(Date:11/20/2009)...ire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ann...s will be held on Monday, December 21, 2009. The p...wo special resolutions. The first special resoluti...substantially all of the assets of NUCRYST, substa...chase agreement dated November 10, 2009 among the ...
(Date:11/20/2009)...re/ -- Following a recall by Unilever The Stop &am...d,s Country Crock ® Side Dishes DELUXE Chedda...ide Dishes DELUXE Four Cheese Pasta due to an unde... dates and UPCs are affected: ,, Shedd,s Count...i Rice 21 oz, UPC 027400218316, Best By NOV 29 09 ...
Breaking Medicine News(10 mins):Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:New Haven Dental Group Expands Their Vision 2Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2
... facility on Sand Canyon Avenue , ...- Hoag Memorial Hospital Presbyterian has reached ...tate Investment Trust headquartered in Long Beach,...Tenet Healthcare Corporation (NYSE: THC) as Irvine...
... today announced a revised date to report its 2008.... ev3 will now report its 2008 second quarter,and ... 2008, after regular,market trading hours., The c...w its second quarter operating results and future,...
... Experience it at http://SutterHealth.org/an... an e-patient?,Studies show that 80 percent of Ame...ion. Thanks to Web 2.0, e-patients now have even m...alreport ,and you,ll see one of the ways Sutter He...
...ent-resistant, study shows , , THURSDAY, J...e evidence that a new AIDS drug brings significant...ents. , The drug, known as raltegravir (Isentress)...y 24 issue of the New England Journal of Medicine...
...lth and,safety services company, today announced t...les to Living Abroad.com and its multi-national em...-filled online guides to trusted,medical care in h...e assigned abroad on topics such as health service...
...Frank,Ervolino, ND, investigated a product that cl...isks associated with stimulants. He reports that,A...tural product from Zurich,Pharmaceuticals, makes n...DC estimates that greater than 30% of adults are o...
Other Medicine News:Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2
(Date:11/20/2009).... 20 Cyberonics, Inc. (N...sident and Chief Executive Officer, and Greg Brown...st Annual Piper Jaffray Health Care Conference in ...M EST. The conference session and webcast will be.... Piper Jaffray will host a webcast of the presen...
(Date:11/20/2009)...J., Nov. 20 Soligenix, I...ompany), formerly known as DOR BioPharma, Inc., a ...that it has formed a consortium to develop thermos...pidly acting vaccines. Soligenix received a $9.4 m...y and Infectious Diseases (NIAID), a division of t...
(Date:11/19/2009)...o., Nov. 19 In a series ...ience, Heska Corporation (Nasdaq: HSKA ) ("Heska"...ts new and improved website. The upgraded site is...and programming to align the site with the company..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 1Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 2Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 3Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 4Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 5Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 6Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 7Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 8Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 9Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 10Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 11Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 12Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 13Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 14Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 15Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 16Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 17Narconon Trois Rivieres Cites Hillbilly Heroin as Canadian Drug Addiction Crisis 52510 1Narconon Trois Rivieres Cites Hillbilly Heroin as Canadian Drug Addiction Crisis 52510 2Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 1Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 2Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 3
...e SNS-595 to Next Stage of Phase 2 Trial Achieved,...OR RELEASE AT 3:30 P.M. EDT, TODAY/ -- Sunesis Pha...age biopharmaceutical company developing novel,ant...liminary results from,the first stage of the compa...oduct candidate, SNS-595, in platinum-resistant ov...
...WASHINGTON, Oct. 23 Boston,Scientific Corporation...,results from its CABERNET and BEACH carotid arter...the effectiveness of stenting with embolic,protect...ectomy (CEA), the,surgical treatment for carotid a...esults were presented by L. Nelson Hopkins, M.D., ...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 2Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 3Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 4Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 5Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 2Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 3Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 4Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results 5
Bledsoe Extender Knee Brace
Bledsoe Post-Op Knee Brace
Bledsoe Basic Knee Brace
Extensor™ Patellar Knee Support with Lateral Strap
Medicine Products: